Cited by 135Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentMultiple Myeloma Research and Treatments

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Open access

Yang, Guang, Buhrlage, Sara J., Tan, Li, Liu, Xia, Chen, Jie, Xu, Lian, Tsakmaklis, Nicholas, Chen, Jiaji G., Patterson, Christopher J., Brown, Jennifer R., Castillo, Jorge J., Zhang, Wei, Zhang, Xiaofeng, Liu, Shuai, Cohen, Philip, Hunter, Zachary R., Gray, Nathanael, Treon, Steven P.·2016·Blood

DOI 10.1182/blood-2016-01-695098

Open this paper in CoChat — free account Open PDF

Abstract

Activating mutations in MYD88 are present in ∼95% of patients with Waldenström macroglobulinemia (WM), as well as other B-cell malignancies including activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL). In WM, mutated MYD88 triggers activation of Bruton tyrosine kinase (BTK). Ibrutinib, a pleiotropic kinase inhibitor that targets BTK, is highly active in patients with mutated MYD88. We observed that mutated MYD88 WM and ABC DLBCL cell lines, as well as primary WM cells show enhanced hematopoietic cell kinase (HCK) transcription and activation, and that HCK is activated by interleukin 6 (IL-6). Over-expression of mutated MYD88 triggers HCK and IL-6 transcription, whereas knockdown of HCK reduced survival and attenuated BTK, phosphoinositide 3-kinase/AKT, and mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in mutated MYD88 WM and/or ABC DLBCL cells. Ibrutinib and the more potent HCK inhibitor A419259, blocked HCK activation and induced apoptosis in mutated MYD88 WM and ABC DLBCL cells. Docking and pull-down studies confirmed that HCK was a target of ibrutinib. Ibrutinib and A419259 also blocked adenosine triphosphate binding to HCK, whereas transduction of mutated MYD88 expressing WM cells with a mutated HCK gatekeeper greatly increased the half maximal effective concentration for ibrutinib and A419259. The findings support that HCK expression and activation is triggered by mutated MYD88, supports the growth and survival of mutated MYD88 WM and ABC DLBCL cells, and is a direct target of ibrutinib. HCK represents a novel target for therapeutic development in MYD88-mutated WM and ABC DLBCL, and possibly other diseases driven by mutated MYD88.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2016-01-695098

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Open Babel: An open chemical toolbox
O'Boyle, N. M., Banck, M. S., James, C. A. J., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-33 · Cited by 10,745
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,560
PROMO: detection of known transcription regulatory elements using species-tailored searches
Messeguer, X., Escudero, R., Farré, D., Núñez, Ó., Martı́nez, J., & Albà, M. M. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.2.333 · Cited by 1,371
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P. S., Manning, R. J., Patterson, C. J., Tripsas, C. K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,316
Self-citation
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 1×
“It also remains possible that mutations in the gatekeeper site of HCK could contribute to ibrutinib resistance, akin to that observed with BTK mutations in chronic lymphocytic leukemia patients, and warrant examination.(40) Finally, the potential to developmore potent HCK inhibitors is suggested by these findings.”
Result
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G. W., Lih, C., Williams, P. M., Shaffer, A. L., Gerecitano, J. F., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,155
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“5 nM) and well within the pharmacologically achievable levels of ibrutinib.(10,39) We provide definitive evidence in this report that HCK is a target of ibrutinib using docking models, direct pull-down experiments with biotinylated ibrutinib, cellular target engagement, and cellular rescue with inhibitor-resistant mut…”
Background

Show all 44 references

Sorted by citations

Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,092
Self-citation
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Treon, S. P., Castillo, J. J., Skarbnik, A. P. Z., Soumerai, J. D., Ghobrial, I. M., Guerrera, M. L., Meid, K., & Yang, G. (2020) · Blood · doi:10.1182/blood.2020006288 · Cited by 907
Self-citation
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Tam, C. S. L., Opat, S., D’Sa, S., Jurczak, W. J., Lee, H., Cull, G., Owen, R. G., Marlton, P. V., Wahlin, B. E., García‐Sánz, R., et al. (2020) · Blood · doi:10.1182/blood.2020006844 · Cited by 466
Self-citation
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Dimopoulos, M. A., Trotman, J., Tedeschi, A., Matous, J., Macdonald, D., Tam, C. S. L., Tournilhac, O., Ma, S., Oriol, A., Heffner, L. T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30632-5 · Cited by 240
Self-citation
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Treon, S. P., Gustine, J. N., Meid, K., Yang, G., Xu, L., Liu, X., Demos, M. G., Kofides, A., Tsakmaklis, N., Chen, J. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.6426 · Cited by 182
Self-citation
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Self-citation
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
Treon, S. P., Xu, L., Guerrera, M. L., Jiménez, C., Hunter, Z. R., Liu, X., Demos, M. G., Gustine, J. N., Chan, G., Munshi, M. N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02314 · Cited by 169
Self-citation
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Alu, A., Lei, H., Han, X., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01353-w · Cited by 159
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Treon, S. P., Meid, K., Gustine, J. N., Yang, G., Xu, L., Liu, X., Patterson, C. J., Hunter, Z. R., Branagan, A. R., Laubach, J. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00555 · Cited by 160
Self-citation
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
Castillo, J. J., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D’Sa, S., Kersten, M. J., Leblond, V., Minnema, M. C., Owen, R. G., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30224-6 · Cited by 148
Self-citation
The diagnosis and treatment of primary vitreoretinal lymphoma: a review
Pulido, J. S., Johnston, P. B., Nowakowski, G. S., Castellino, A., & Raja, H. (2018) · International Journal of Retina and Vitreous · doi:10.1186/s40942-018-0120-4 · Cited by 129
MYD88 L265P Mutation in Lymphoid Malignancies
Yu, X., Li, W., Deng, Q., Li, L., Hsi, E. D., Young, K. H., Zhang, M., & Li, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0215 · Cited by 125
Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia
Hunter, Z. R., Yang, G., Xu, L., Liu, X., Castillo, J. J., & Treon, S. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0814 · Cited by 111
Self-citation
MYD 88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
Treon, S. P., Gustine, J. N., Xu, L., Manning, R. J., Tsakmaklis, N., Demos, M. G., Meid, K., Guerrera, M. L., Munshi, M. N., Chan, G., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.15049 · Cited by 107
Self-citation
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
Hunter, Z. R., Xu, L., Tsakmaklis, N., Demos, M. G., Kofides, A., Jiménez, C., Chan, G., Chen, J. G., Liu, X., Munshi, M. N., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022962 · Cited by 94
Self-citation
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
Chen, J. G., Liu, X., Munshi, M., Xu, L., Tsakmaklis, N., Demos, M. G., Kofides, A., Guerrera, M. L., Chan, G. G., Patterson, C. J., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811752 · Cited by 88
Self-citation
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
Naeem, A., Utro, F., Wang, Q., Cha, J., Vihinen, M., Martindale, S., Zhou, Y., Ren, Y., Tyekucheva, S., Kim, A. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008447 · Cited by 87
Self-citation
MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
de Groen, R. A. L., Schrader, A. M. R., Kersten, M. J., Pals, S. T., & Vermaat, J. S. P. (2019) · Haematologica · doi:10.3324/haematol.2019.227272 · Cited by 86
Circulating tumor DNA profiling reveals clonal evolution and real‐time disease progression in advanced hepatocellular carcinoma
Cai, Z., Chen, G., Zeng, Y., Dong, X., Lin, M., HUANG, X.-H., Zhang, D., Liu, X., & Liu, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30798 · Cited by 84
Self-citation
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
Abeykoon, J. P., Paludo, J., King, R. L., Ansell, S. M., Gertz, M. A., LaPlant, B. R., Halvorson, A. E., Gonsalves, W. I., Dingli, D., Fang, H., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24955 · Cited by 70
Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
Feng, Y., Duan, W., Cu, X., Liang, C., & Xin, M. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1594777 · Cited by 60
From identification of the BTK kinase to effective management of leukemia
Smith, C. I. E. (2016) · Oncogene · doi:10.1038/onc.2016.343 · Cited by 57
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK
Dhami, K., Chakraborty, A., Gururaja, T. L., Cheung, L. W. K., Sun, C. C., DeAnda, F., & Huang, X. (2022) · Science Signaling · doi:10.1126/scisignal.abg5216 · Cited by 50
Primary vitreoretinal lymphoma
Kalogeropoulos, D., Vartholomatos, G., Mitra, A., Elaraoud, I., Ch’ng, S. W., Zikou, A. K., Papoudou‐Bai, A., Moschos, M. M., Kanavaros, P., & Kalogeropoulos, C. D. (2019) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2018.12.008 · Cited by 50
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Munshi, M. N., Liu, X., Chen, J. G., Xu, L., Tsakmaklis, N., Demos, M. G., Kofides, A., Guerrera, M. L., Jiménez, C., Chan, G., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0277-6 · Cited by 49
Self-citation
Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders
Thompson, P. A., & Tam, C. (2023) · Blood Journal · doi:10.1182/blood.2023020240 · Cited by 42
A Head-To-Head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients with Waldenström Macroglobulinemia
Tam, C. S. L., Leblond, V., Novotny, W. F., Owen, R. G., Tedeschi, A., Atwal, S. K., Cohen, A. C., Huang, J. Q., & Buske, C. (2018) · Future Oncology · doi:10.2217/fon-2018-0163 · Cited by 38
Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma
Wenzl, K., Manske, M. K., Sarangi, V., Asmann, Y. W., Greipp, P. T., Schoon, H. R., Braggio, E., Maurer, M. J., Feldman, A. L., Witzig, T. E., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0130-3 · Cited by 40
CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia
Gustine, J. N., Xu, L., Tsakmaklis, N., Demos, M. G., Kofides, A., Chen, J. G., Liu, X., Munshi, M. N., Guerrera, M. L., Chan, G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000635 · Cited by 38
Self-citation
Hematopoietic Cell Kinase (HCK) Is Essential for NLRP3 Inflammasome Activation and Lipopolysaccharide-Induced Inflammatory Response In Vivo
Kong, X., Liao, Y.-J., Zhou, L., Zhang, Y., Cheng, J.-B., Yuan, Z.-Q., & Wang, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.581011 · Cited by 38
MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies
Alcoceba, M., García‐Álvarez, M., Medina, A., Maldonado, R., González‐Calle, V., Chillón, C., Sarasquete, M. E., González, M., García‐Sánz, R., & Jiménez, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105570 · Cited by 37
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
An, G., Zhou, D., Cheng, S., Zhou, K., Li, J., Zhou, J., Xie, L., Jin, J., Zhong, L., Yan, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0539 · Cited by 37
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing
Zamò, A., Pischimarov, J., Schlesner, M., Rosenstiel, P. C., Bomben, R., Horn, H., Grieb, T., Nedeva, T., López, C., Haake, A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.270 · Cited by 35
Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges
Allegra, A., Pioggia, G., Tonacci, A., Musolino, C., & Gangemi, S. (2020) · Cancers · doi:10.3390/cancers12061581 · Cited by 35
Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas
Islam, S., Qi, W., Morales, C., Cooke, L. S., Spier, C. M., Weterings, E., & Mahadevan, D. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0089 · Cited by 29
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
Yang, G., Wang, J., Tan, L., Munshi, M. N., Liu, X., Kofides, A., Chen, J. G., Tsakmaklis, N., Demos, M. G., Guerrera, M. L., et al. (2021) · Blood · doi:10.1182/blood.2021011405 · Cited by 30
Self-citation
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
Kofides, A., Hunter, Z. R., Xu, L., Tsakmaklis, N., Demos, M. G., Munshi, M. N., Liu, X., Guerrera, M. L., Leventoff, C. R., White, T. P., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000624 · Cited by 30
Self-citation
FCGR1A Serves as a Novel Biomarker and Correlates With Immune Infiltration in Four Cancer Types
Xu, J.-L., & Guo, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.581615 · Cited by 26
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors
Tam, C. S. L., Balendran, S., & Blombery, P. A. (2025) · Blood · doi:10.1182/blood.2024026672 · Cited by 29
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
Treon, S. P., Meid, K., Tripsas, C. K., Heffner, L. T., Eradat, H. A., Badros, A. Z., Xu, L., Hunter, Z. R., Yang, G., Patterson, C. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1918 · Cited by 27
Self-citation
Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma
Lantermans, H. C., Minderman, M., Kuil, A., Kersten, M. J., Pals, S. T., & Spaargaren, M. (2020) · Leukemia · doi:10.1038/s41375-020-0934-6 · Cited by 27
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
Liu, X., Chen, J. G., Munshi, M. N., Hunter, Z. R., Xu, L., Kofides, A., Tsakmaklis, N., Demos, M. G., Guerrera, M. L., Chan, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000947 · Cited by 25
Self-citation
What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo, J. J., & Treon, S. P. (2019) · Leukemia · doi:10.1038/s41375-019-0592-8 · Cited by 23
Self-citation
Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review
Lin, A. Y., Cuttica, M. J., Ison, M. G., & Gordon, L. I. (2020) · eJHaem · doi:10.1002/jha2.98 · Cited by 22
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia
Treon, S. P., Sarosiek, S., & Castillo, J. J. (2024) · Blood · doi:10.1182/blood.2022017235 · Cited by 23
Self-citation
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Fotiou, D., & Dimopoulos, M. A. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620721989586 · Cited by 23
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
Gustine, J. N., Sarosiek, S., Flynn, C. A., Meid, K., Leventoff, C. R., White, T., Guerrera, M. L., Xu, L., Kofides, A., Tsakmaklis, N., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279112 · Cited by 21
Self-citation
Genomic Landscape of Waldenström Macroglobulinemia
Treon, S. P., Xu, L., Liu, X., Hunter, Z. R., Yang, G., & Castillo, J. J. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.05.003 · Cited by 21
Self-citation
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
Kifle, Z. D. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100116 · Cited by 20
New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM
Scala, S., D’Alterio, C., Milanesi, S., Castagna, A., Carriero, R., Farina, F. M., Locati, M., & Borroni, E. M. (2020) · Vaccines · doi:10.3390/vaccines8020164 · Cited by 18
STAT3 is required for Smo‐dependent signaling and mediates Smo‐targeted treatment resistance and tumorigenesis in Shh medulloblastoma
Yuan, L., Zhang, H., Liu, J., Malhotra, A., Dey, A., Yu, B., Jella, K. K., McSwain, L., Schniederjan, M., & MacDonald, T. J. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13097 · Cited by 20
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
Munshi, M. N., Liu, X., Kofides, A., Tsakmaklis, N., Guerrera, M. L., Hunter, Z. R., Palomba, M. L., Argyropoulos, K. V., Patterson, C. J., Canning, A. G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006147 · Cited by 17
Self-citation
New developments in the management of Waldenström macroglobulinemia
Abeykoon, J. P., Yanamandra, U., & Kapoor, P. (2017) · Cancer Management and Research · doi:10.2147/cmar.s94059 · Cited by 17
HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML
Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02007-4 · Cited by 17
Self-citation
Insights on hematopoietic cell kinase: An oncogenic player in human cancer
Luo, S., Du, S., Tao, M., Cao, J., & Cheng, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114339 · Cited by 18
Recent advances in hematopoietic cell kinase in cancer progression: Mechanisms and inhibitors
Zeng, Q., He, J., Chen, X., Yuan, Q., Yin, L., Liang, Y., Zu, X., & Shen, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116932 · Cited by 15
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials
Castillo, J. J., Gustine, J. N., Meid, K., Flynn, C. A., Demos, M. G., Guerrera, M. L., Jiménez, C., Kofides, A., Liu, X., Munshi, M. N., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000363 · Cited by 15
Self-citation
Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies
Bagratuni, T., Markou, A. N., Patseas, D., Mavrianou‐Koutsoukou, N., Aktypi, F. D., Liacos, C., Sklirou, A. D., Theodorakakou, F., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005354 · Cited by 15
Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia
Hao, M., Barlogie, B., Tricot, G. J. K., Liu, L., Qiu, L., Shaughnessy, J. D., & Zhan, F. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1435 · Cited by 14
Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors
Lü, L., Zhu, F., Li, Y., Kimpara, S., Hoang, N. M., Pourdashti, S., & Rui, L. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0203-y · Cited by 14
Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
Παπανώτα, Α.-Μ., Ntanasis‐Stathopoulos, I., Kastritis, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s183997 · Cited by 14
Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88
Sacco, A., Federico, C., Giacomini, A., Caprio, C., Maccarinelli, F., Todoerti, K., Favasuli, V. K., Anastasia, A., Motta, M., Russo, D., et al. (2020) · Blood · doi:10.1182/blood.2020008414 · Cited by 13
A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers
Rao, S., Du, G., Hafner, M. A., Subramanian, K., Sorger, P. K., & Gray, N. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006805 · Cited by 12
Self-citation
Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00559-4 · Cited by 12
Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.
Bibas, M., Castillo, J. J., & Sarosiek, S. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.061 · Cited by 14
Self-citation
Polyneuropathy Associated with IgM Monoclonal Gammopathy; Advances in Genetics and Treatment, Focusing on Anti-MAG Antibodies
van de Mortel, J. P. M., D’Sa, S., Vrancken, A. F. J. E., Notermans, N. C., Vos, J. M. I., & Minnema, M. C. (2022) · Hemato · doi:10.3390/hemato3040045 · Cited by 10
FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma
Sun, K., Fei, X., Xu, M., Xu, R., & Xu, M. (2022) · Journal of Oncology · doi:10.1155/2022/9499317 · Cited by 11
Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis—a review of current knowledge and future directions
Wang, S., Zhou, S.-W., Gao, J., & Wang, L. (2025) · Blood Science · doi:10.1097/bs9.0000000000000233 · Cited by 9
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance
Drandi, D., Decruyenaere, P., Ferrante, M., Offner, F. C., Vandesompele, J., & Ferrero, S. (2022) · Diagnostics · doi:10.3390/diagnostics12040969 · Cited by 8
MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8
Mandato, E., Yan, Q., Ouyang, J., Paczkowska, J., Qin, Y., Hao, Y., Bojarczuk, K., Hansen, J., Chapuy, B., Rodig, S. J., et al. (2023) · Blood · doi:10.1182/blood.2023019865 · Cited by 8
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemiaPreprint
Joseph, R. E., Wales, T. E., Jayne, S., Britton, R. G., Fulton, D. B., Engen, J. R., Dyer, M. J. S., & Andreotti, A. H. (2024) · eLife · doi:10.7554/elife.95488 · Cited by 8
Novel approaches to targeting MYD88 in Waldenström macroglobulinemia
Castillo, J. J., Hunter, Z. R., Yang, G., & Treon, S. P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1343661 · Cited by 7
Self-citation
Diagnosis and Molecular Pathology of Lymphoblastic Leukemias and Lymphomas in the Era of Genomics and Precision Medicine: Historical Evolution and Current Concepts—Part 3: Mature Leukemias/Lymphomas
Kansal, R. (2023) · Lymphatics · doi:10.3390/lymphatics1020012 · Cited by 6
The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
Lantermans, H. C., Ma, F., Kuil, A., van Kesteren, S., Yasinoglu, S. A., Yang, G., Buhrlage, S. J., Wang, J., Gray, N. S., Kersten, M. J., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02207-9 · Cited by 6
Self-citation
How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy
Baron, M., Simon, L., Poulain, S., & Leblond, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0768-4 · Cited by 6
FAK-mediated phosphorylation at Y464 regulates p85β nuclear translocation to promote tumorigenesis of ccRCC by repressing RB1 expression
Zhang, Y., He, B., Zhang, D., Zhang, Y., Chen, C., Zhang, W., Yang, S., Yao, M., Cui, G., Gu, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112188 · Cited by 6
Self-citation
Diagnosis and Management of Waldenstrom's Macroglobulinemia
Treon, S. P., Sarosiek, S., & Castillo, J. J. (2025) · Hematological Oncology · doi:10.1002/hon.70071 · Cited by 5
Self-citation
Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective Inhibition to the BTK/HCK Dual Inhibition - Delving into the Inhibitory Activity of KIN-8194 against BTK, and HCK in the Treatment of Mutated BTKCys481 Waldenström Macroglobulinemia: A Computational Approach
Elamin, G., Aljoundi, A., Alahmdi, M. I., Abo-Dya, N. E., & Soliman, M. E. S. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230208102609 · Cited by 5
Diagnosis and Risk Stratification in Waldenström Macroglobulinemia
Zanwar, S., & Kapoor, P. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7024 · Cited by 5
Ibrutinib in the management of Waldenstrom macroglobulinemia
Yosef, A., Touloukian, E. Z., & Nambudiri, V. E. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218786037 · Cited by 5
The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia
Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1791705 · Cited by 5
Lymphoplasmacytic lymphoma in a patient with Birt–Hogg–Dubé syndrome
Kurata, K., Matsumoto, H., Jimbo, N., Yakushijin, K., Yamamoto, K., Ito, M., Nakamachi, Y., Matsuoka, H., Saegusa, J., Seyama, K., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02970-2 · Cited by 5
DCC-2036 inhibits osteosarcoma via targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy
He, J., Yin, L., Yuan, Q., Su, X., Shen, Y., & Deng, Z. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03778-2 · Cited by 4
Clinicopathological value of hematopoietic cell kinase overexpression in laryngeal squamous cell carcinoma tissues
Xia, S., Li, J., Yan, S.-B., Huang, Z., Liu, Z., Jing, S.-W., Li, D., Song, C. H., Chen, Y., Wang, L., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154534 · Cited by 4
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia
Richardson, K., Castillo, J. J., Sarosiek, S., Branagan, A. R., Flynn, C. A., Meid, K., Gustine, J. N., Liu, X., Kofides, A., Liu, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012111 · Cited by 4
Self-citation
ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells
Munshi, M. N., Liu, X., Kofides, A., Tsakmaklis, N., Hunter, Z. R., Guerrera, M. L., Canning, A., Gustine, J. N., Liu, S., Hatcher, J. M., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19756 · Cited by 4
Self-citation
Future therapeutic options for patients with Waldenström macroglobulinemia
Castillo, J. J., Hunter, Z. R., Yang, G., Argyropoulos, K. V., Palomba, M. L., & Treon, S. P. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.08.021 · Cited by 4
Self-citation
Deciphering the Key Pharmacological Pathways and Targets of Yisui Qinghuang Powder That Acts on Myelodysplastic Syndromes Using a Network Pharmacology‐Based Strategy
Han, Z., Song, L., Qi, K., Ding, Y., Wei, M., & Yongcun, J. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/8877295 · Cited by 4
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
Castillo, J. J., Sarosiek, S., Flynn, C. A., Leventoff, C. R., Little, M., White, T., Meid, K., & Treon, S. P. (2022) · eJHaem · doi:10.1002/jha2.493 · Cited by 4
Self-citation
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Ababneh, O. E., Abushukair, H. M., Qarqash, A., Syaj, S., & Hadidi, S. A. (2022) · Clinical Hematology International · doi:10.1007/s44228-022-00007-5 · Cited by 4
Orelabrutinib and rituximab regimen combined with intravitreal methotrexate for treatment of primary vitreoretinal lymphoma: a case report and literature review
Liu, L., Qiao, R., Zhang, X., & Li, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1800529 · Cited by 3
Self-citation
Review of BCL2 inhibitors for the treatment of Waldenström’s macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma
Tomkins, O. M., & D’Sa, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1490202 · Cited by 3
Multiple Myeloma in a Patient with Birt-Hogg-Dubé Syndrome
Matsumura, F., Sakamoto, T., Kai, H., Usui, T., Kawanishi, K., Matsuoka, R., Ishitsuka, K., Makishima, K., Suma, S., Maruyama, Y., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4985-24 · Cited by 3
Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenström macroglobulinemia
Wan, Y., Cheng, Y., Liu, Y., Shen, L., & Hou, J. (2021) · Cancer · doi:10.1002/cncr.33454 · Cited by 3
Non-coding NFKBIZ 3′ UTR mutations promote cell growth and resistance to targeted therapeutics in diffuse large B-cell lymphomaPreprint
Arthur, S. E., Gao, J., Healy, S., Rushton, C. K., Thomas, N., Hilton, L. K., Dreval, K., Tang, J. S., Alcaide, M., Cojocaru, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.22.445261 · Cited by 3
Targeting kinase resistance in CML: Efficacy of phytoconstituents through molecular docking and dynamics simulations
Kashyap, A., Srivastava, R., & Prasad, R. C. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100200 · Cited by 2
Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Piazza, F., Paolo, V. D., Scapinello, G., Manni, S., Trentin, L., & Quintieri, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.801124 · Cited by 2
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Khan, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050676 · Cited by 2
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Joseph, R. E., Wales, T. E., Jayne, S., Britton, R. G., Fulton, D. B., Engen, J. R., Dyer, M. J. S., & Andreotti, A. H. (2024) · eLife · doi:10.7554/elife.95488.3 · Cited by 3
Genomic landscape of Waldenström's macroglobulinemia
Treon, S. P., Hunter, Z. R., Branagan, A. R., & Castillo, J. J. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000228 · Cited by 2
Self-citation

Authors: Yang, G., Buhrlage, S. J., Tan, L., Liu, X., Chen, J., Xu, L., Tsakmaklis, N., Chen, J. G., Patterson, C. J., Brown, J. R., Castillo, J. J., Zhang, W., Zhang, X., Liu, S., Cohen, P., Hunter, Z. R., Gray, N., & Treon, S. P.
Affiliations: Harvard University (US)
University of Massachusetts Boston (US)
University of Dundee (GB)
ORCID: Yang, Guang
Buhrlage, Sara J.
Tan, Li
Liu, Xia
Chen, Jie
Chen, Jiaji G.
Patterson, Christopher J.
Brown, Jennifer R.
Castillo, Jorge J.
Zhang, Wei
Zhang, Xiaofeng
Liu, Shuai
Cohen, Philip
Hunter, Zachary R.
Gray, Nathanael
Treon, Steven P.
Venue: Blood
Publisher: American Society of Hematology
Published: 2016-06-23
Volume: 127
Issue: 25
Pages: 3237-3252
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2016-01-695098
OpenAlex: W2347186599
Cited by: 135
References: 44
Citations by year: 2026: 7 · 2025: 10 · 2024: 13 · 2023: 10 · 2022: 14 · 2021: 22 · 2020: 19 · 2019: 11 · 2018: 16 · 2017: 9 · 2016: 4
FWCI: 9.67
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
Funders: Leukemia and Lymphoma Society
Medical Research Council (MR/K000985/1)
Topics: Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Keywords: hematopoietic cell kinase, MYD88 mutation, Waldenström macroglobulinemia, ibrutinib, Bruton's tyrosine kinase, interleukin-6, cell survival, apoptosis, PI3K/Akt signaling, ERK signaling, drug resistance
MeSH terms: Adenine, Antineoplastic Agents, Cell Survival, Humans, Waldenstrom Macroglobulinemia, Piperidines, Pyrazoles, Pyrimidines, Transcriptional Activation, Interleukin-6, Gene Expression Regulation, Leukemic, Lymphoma, Large B-Cell, Diffuse, Cell Line, Tumor, Mutant Proteins, Proto-Oncogene Proteins c-hck, Myeloid Differentiation Factor 88, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks